News
Serum Institute of India starts manufacturing Codagenix’s nasal COVID-19 vaccine
Serum Institute of India has started manufacturing COVID-19 vaccine candidate developed by Codagenix Inc, the US biotech firm said in a statement. Dubbed as CDX-005, the coronavirus vaccine candidate has completed pre-clinical animal studies. The company aims to initiate...
News
Oxgene introduces TESSA technology for plasmid-free manufacturing system for Adeno-associated virus
Oxgene, a biotechnology company designing and developing scalable gene therapy technologies, has announced the launch of its scalable, plasmid-free manufacturing system for Adeno-associated virus (AAV). Oxgene’s new TESSA technology addresses industry-wide challenges associated with robust and reproducible AAV manufacture...
Clinical Trials
Bharat Biotech to collaborate with Washington University School of Medicine on COVID-19 nasal vaccine
Vaccine maker Bharat Biotech has entered into an agreement with Washington University School of Medicine in St. Louis as part of which it will conduct trials, produce and market an intranasal vaccine for COVID-19 being developed by the latter.
It...
Clinical Trials
I-Mab receives China NMPA clearance to begin phase 1 trial of lemzoparlimab in relapsed/refractory advanced lymphoma
I-Mab, a clinical stage biopharmaceutical company, announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for lemzoparlimab (also known as TJC4) to initiate a...
News
US FDA grants fast track status to Gyroscope’s GT005 to treat dry age-related macular degeneration
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, announced that the US FDA has granted Fast Track designation to GT005 for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).
GT005 is an investigational one-time...
News
AstraZeneca’s Lynparza recommended by the EMA for HRD-positive advanced ovarian cancer
AstraZeneca and MSD’s Lynparza (olaparib) has been recommended for marketing authorisation across the European Union for the first-line maintenance treatment with bevacizumab for patients with homologous recombination deficient (HRD)-positive advanced ovarian cancer.
This came after the Committee for Medicinal Products...
News
Bristol Myers Squibb Completes Acquisition of Forbius
Bristol Myers Squibb announced that it has successfully completed its transaction to acquire Forbius for their TGF-beta program, including its lead investigational asset AVID200, currently in Phase 1 for oncology and fibrosis.
“We are pleased to complete the transaction with...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read